טוען...
MEK1 is required for the development of NRAS-driven leukemia
The dual-specificity kinases MEK1 and MEK2 act downstream of RAS/RAF to induce ERK activation, which is generally considered protumorigenic. Activating MEK mutations have not been discovered in leukemia, in which pathway activation is caused by mutations in upstream components such as RAS or Flt3. T...
שמור ב:
| הוצא לאור ב: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Impact Journals LLC
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5348309/ https://ncbi.nlm.nih.gov/pubmed/27741509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12555 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|